News

An armoured allogeneic “off-the-shelf”gamma delta CAR T cell therapy, ADI-270 targets CD70-positive cancers. ADI-270 is engineered to target CD70 by using CD27 as the natural receptor binding moiety.

This decision follows a positive recommendation from the Committee for Medicinal Products for Human Use and is based on the results of the FLAURA2 Phase III trial. The

This approval marks a significant milestone for the company, indicating that its product is therapeutically equivalent to the reference listed Tibsovo Tablets, 250mg of Servier Pharmaceuticals. Ivosidenib is

The funding will support ongoing clinical trials for X-Linked Retinitis Pigmentosa (XLRP) and advance the company’s Dry Age-related Macular Degeneration (dAMD) programme. The investment round included contributions from

A lead radiopharmaceutical of the company, 225Ac-FL-020 acts on prostate-specific membrane antigen (PSMA). The fast track programme of the FDA aims to expedite the development and regulatory review

This marks a significant advancement as sigx1094 is the world’s first targeted therapy for DGC, a condition with a notable lack of effective treatments. The company is set

This endorsement is a significant step towards the authorisation of the vaccine in the European Union (EU) to prevent lower respiratory tract disease caused by the respiratory syncytial

This designation is a significant milestone in the development of TUB-040, which is based on Tubulis’ proprietary P5 technology. TUB-040 is a next-generation NaPi2b-targeting Exatecan ADC with superior

Ohtuvayre is claimed to be the first inhaled medication with a unique mechanism of action for COPD maintenance therapy in more than two decades. A dual inhibitor of